TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23592708

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 2706

Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 2706
Study: 19926194

Group type: EXPERIMENTAL
Intervention: Metronome guidance during CPR
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no metronome) during CPR
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Metronome guidance during CPR with bag/endotracheal tube
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no metronome) during CPR with bag/endotracheal tube
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Metronome guidance with secured airway
Number of subjects: 68
Study: 19006745

Group type: EXPERIMENTAL
Intervention: Half-moon supracapsular technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stop-and-chop technique
Number of subjects: 100
Study: 16652321

Group type: EXPERIMENTAL
Intervention: DAART
Number of subjects: 82

Group type: COMPARATOR
Intervention: IDU-methadone (Control)
Number of subjects: 82

Group type: COMPARATOR
Intervention: IDU-nonmethadone (Control)
Number of subjects: 82

Group type: COMPARATOR
Intervention: non-IDU (Control)
Number of subjects: 82
Study: 12791811

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET with intravenous injection of 120 MBq (18)F‐FDG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET
Number of subjects: 11
Study: 11004058

Group type: EXPERIMENTAL
Intervention: IV lidocaine (bolus 2 mg/kg, then infusion 3 mg/kg/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 8972022

Group type: EXPERIMENTAL
Intervention: Dalteparin (30 anti-Xa IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalteparin (60 anti-Xa IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 anti-Xa IU/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 0
Study: 1319311

Group type: EXPERIMENTAL
Intervention: Oral itraconazole, 200 mg twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous amphotericin B, 0.6 mg/kg/day (or 0.3 mg/kg/day plus flucytosine, 150 mg/kg/day for some Candida infections)
Number of subjects: 32
Study: 6230612

Group type: EXPERIMENTAL
Intervention: naproxen-sodium (825 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: paracetamol (1,000 mg)
Number of subjects: 124
Study: 31752981

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with temozolomide (TMZ)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 250
Study: 29378658

Group type: EXPERIMENTAL
Intervention: Payment for performance (P4P)
Number of subjects: 3000
Study: 26925771

Group type: EXPERIMENTAL
Intervention: Training in Evidence-Based Medicine (EBM) for 6 months
Number of subjects: 45
Study: 25066654

Group type: EXPERIMENTAL
Intervention: nutritional counseling + symbiotic
Number of subjects: 18

Group type: COMPARATOR
Intervention: nutritional counseling + placebo
Number of subjects: 18
Study: 22859907

Group type: EXPERIMENTAL
Intervention: Rap System of Stress Stimulation (RSSS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 18853138

Group type: EXPERIMENTAL
Intervention: Bile acids (5 micromol/l)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exogenous surfactant (poractant-alfa)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bile acids (lower concentrations)
Number of subjects: 23
Study: 17599855

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultralente insulin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of glargine and Ultralente
Number of subjects: 22
Study: 16035063

Group type: EXPERIMENTAL
Intervention: Low-dose HCIG (75 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose HCIG (200 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study: 12350438

Group type: EXPERIMENTAL
Intervention: Young adults (mean age=21.4+/‐2.5 years)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Older adults (mean age=75.5+/‐6.3 years)
Number of subjects: 34
Study: 10417490

Group type: EXPERIMENTAL
Intervention: Activated charcoal alone (25 g in 200 ml water)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Activated charcoal combined with gastric lavage (25 g charcoal after lavage)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (200 ml water)
Number of subjects: 9
Study: 7766171

Group type: EXPERIMENTAL
Intervention: Isomaltooligosaccharides mixture (IMO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydrogenated derivative of isomaltooligosaccharides (IMO‐H)
Number of subjects: 6
Study: 2187496

Group type: EXPERIMENTAL
Intervention: Increased contact efforts for breast cancer screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimum contact efforts for breast cancer screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reluctant participants
Number of subjects: 0
Study: 7001668

Group type: EXPERIMENTAL
Intervention: Mite-free bedding
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ordinary bedding
Number of subjects: 21
Study: 29190398

Group type: EXPERIMENTAL
Intervention: Cigarette with warning 'Smoking kills'
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Green cigarette
Number of subjects: 997

Group type: COMPARATOR
Intervention: Standard cigarette
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Composite measure of cigarette perceptions
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Likelihood of trying the cigarettes
Number of subjects: 997
Study: 28866454

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 40
Study: 25624764

Group type: EXPERIMENTAL
Intervention: Single-level thoracic manipulation (STM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Multiple-level thoracic manipulation (MTM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (prone lying)
Number of subjects: 48
Study: 24068158

Group type: EXPERIMENTAL
Intervention: Radial artery harvest
Number of subjects: 751

Group type: COMPARATOR
Intervention: Saphenous vein harvest
Number of subjects: 751
Study: 21539530

Group type: EXPERIMENTAL
Intervention: Lower-body resistive heating (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Forced-air heating (n = 14)
Number of subjects: 28
Study: 18045712

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate (Meiji Black Chocolate 45 g, 550 mg cacao polyphenol/day, 200 kcal)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-flavonoid white chocolate (Meiji White Chocolate 35 g, 0 mg cacao polyphenol/day, 140 kcal)
Number of subjects: 39
Study: 17667613

Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05% ophthalmic emulsion (RESTASIS) twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: lower‐lid punctal plugs (PARASOL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: plugs‐cyclosporine combination
Number of subjects: 30

Group type: COMPARATOR
Intervention: cyclosporine alone
Number of subjects: 30
Study: 15581121

Group type: EXPERIMENTAL
Intervention: Imitation using the same side of their bodies as the model (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imitation using the opposite side of their bodies as the model (Experiment 2)
Number of subjects: 0
Study: 11197288

Group type: EXPERIMENTAL
Intervention: RAP150 group (pantoprazole 40 mg b.i.d., amoxycillin 1 g b.i.d., rifabutin 150 mg o.d.)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: RAP300 group (pantoprazole 40 mg b.i.d., amoxycillin 1 g b.i.d., rifabutin 300 mg o.d.)
Number of subjects: 135

Group type: COMPARATOR
Intervention: QT group (pantoprazole 40 mg b.i.d., metronidazole 250 mg t.i.d., bismuth citrate 240 mg b.i.d., tetracycline 500 mg q.i.d.)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rifabutin-treated patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Quadruple therapy patients
Number of subjects: 135
Study: 9673470

Group type: EXPERIMENTAL
Intervention: Ethnic identification assessment
Number of subjects: 545
Study: 8019124

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 464

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 464
Study: 2673437

Group type: EXPERIMENTAL
Intervention: Tetracosactide (TCS) 2 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dexamethasone (DXM) 20 mg
Number of subjects: 33
Study: 339647

Group type: EXPERIMENTAL
Intervention: 500 mg L-dopa
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.75 mg apomorphine
Number of subjects: 26
Study: 31094354

Group type: EXPERIMENTAL
Intervention: Psychoeducational mobile app plus treatment as usual (TAU)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 660
Study: 28330700

Group type: EXPERIMENTAL
Intervention: Kinesio taping with tension and home exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kinesio taping without tension and home exercises
Number of subjects: 40
Study: 25869422

Group type: EXPERIMENTAL
Intervention: Males with PFP
Number of subjects: 102

Group type: COMPARATOR
Intervention: Controls (males without PFP)
Number of subjects: 102
Study: 23973952

Group type: EXPERIMENTAL
Intervention: Watchman device (Boston Scientific, Natick, MA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amplatzer Cardiac Plug (St Jude Medical, Minneapolis, MN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postprocedural antithrombotic therapy for 6 weeks followed by aspirin
Number of subjects: 80
Study: 21455089

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with bupivacaine 1 mg/mL, epinephrine 2 μg/mL, and fentanyl 2 μg/mL
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 26
Study: 19245413

Group type: EXPERIMENTAL
Intervention: Exercise-based model of hospital and in-home follow-up care (individualized exercise strategies, nurse-conducted home visit, and telephone follow-up for 24 weeks).
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 128
Study: 17085656

Group type: EXPERIMENTAL
Intervention: Preoperative short-term radiotherapy
Number of subjects: 1198

Group type: COMPARATOR
Intervention: No preoperative short-term radiotherapy
Number of subjects: 1198
Study: 13678916

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4809

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 4809

Group type: EXPERIMENTAL
Intervention: Tirofiban or Abciximab
Number of subjects: 4809
Study: 11025866

Group type: EXPERIMENTAL
Intervention: stent-abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: stent-placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: balloon-abciximab
Number of subjects: 0
Study: 9503814

Group type: EXPERIMENTAL
Intervention: Isoptin-retard (240 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study: 8464198

Group type: EXPERIMENTAL
Intervention: Pall PF 30 filter
Number of subjects: 92

Group type: COMPARATOR
Intervention: No filter (control)
Number of subjects: 92
Study: 2931024

Group type: EXPERIMENTAL
Intervention: Ketanserin (intravenous bolus)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketanserin (continuous infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketanserin (discontinued)
Number of subjects: 30
Study: 30066201

Group type: EXPERIMENTAL
Intervention: Palliative care (PC)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Psychosocial care (PSC)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Radiotherapy treatment
Number of subjects: 923

Group type: COMPARATOR
Intervention: Increasing age
Number of subjects: 923
Study: 28874502

Group type: EXPERIMENTAL
Intervention: K-wire with external fixation (Ex-Fix)
Number of subjects: 51

Group type: COMPARATOR
Intervention: K-wire with plaster
Number of subjects: 51
Study: 27033674

Group type: EXPERIMENTAL
Intervention: African Dance three times per week for six months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Educational training on Africana history and culture, and health behaviors three times per week for six months
Number of subjects: 80
Study: 25075834

Group type: EXPERIMENTAL
Intervention: Artesunate administered orally at a daily dose of 2 mg per kilogram of body weight for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy.
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Artesunate administered orally at a daily dose of 4 mg per kilogram of body weight for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy.
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: 6-day course of antimalarial therapy in western Cambodia.
Number of subjects: 1241
Study: 23297639

Group type: EXPERIMENTAL
Intervention: Lactulose administration (30 ml for 1 week)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (surgery without lactulose)
Number of subjects: 58
Study: 20534168

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation plus the Chronic Disease Self‐Management Program (CDSMP) with additional modules on navigating compensation systems and managing return to work.
Number of subjects: 366

Group type: COMPARATOR
Intervention: Vocational rehabilitation alone (control group)
Number of subjects: 366
Study: 18503891

Group type: EXPERIMENTAL
Intervention: Statin administration (Atorvastatin and Pravastatin)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Statin administration
Number of subjects: 108
Study: 11928030

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 40
Study: 9503245

Group type: EXPERIMENTAL
Intervention: Subjects with eating disorders (anorexia nervosa and bulimia nervosa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restrained eaters
Number of subjects: 0
Study: 8277950

Group type: EXPERIMENTAL
Intervention: High sucrose diet (5600 +/- 2100 mg/kg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low sucrose diet with aspartame (38 +/- 13 mg/kg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low sucrose diet with saccharin (12 +/- 4.5 mg/kg/day)
Number of subjects: 48
Study: 2923936

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.5 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 1.0 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (healthy controls and nondepressed psychiatric patients)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Standard 1.0‐mg DST
Number of subjects: 54
Study: 30654925

Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m2
Number of subjects: 399

Group type: COMPARATOR
Intervention: BMI 25 to 29.9 kg/m2
Number of subjects: 399

Group type: COMPARATOR
Intervention: BMI <25 kg/m2
Number of subjects: 399
Study: 27995373

Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular diclofenac
Number of subjects: 60
Study: 26176703

Group type: EXPERIMENTAL
Intervention: 8-week home-reading programme implemented by caregivers
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 13
Study: 23867960

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 113

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 113
Study: 21677076

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Soy Protein (SP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 90
Study: 19252157

Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-structured group intervention
Number of subjects: 120
Study: 16461878

Group type: EXPERIMENTAL
Intervention: Acetaminophen (12.5 mg/kg per dose every 6 hours)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ibuprofen (5 mg/kg per dose every 8 hours)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Alternating acetaminophen and ibuprofen (every 4 hours)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 464
Study: 14970960

Group type: EXPERIMENTAL
Intervention: Amitriptyline (titrated up to 125 mg/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active placebo (benztropine mesylate)
Number of subjects: 39
Study: 11773300

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (four cycles of doxorubicin/cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemotherapy (same regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study: 9009122

Group type: EXPERIMENTAL
Intervention: Ranitidine (group I, N = 8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine plus pirenzepine (group II, N = 12)
Number of subjects: 20
Study: 8312728

Group type: EXPERIMENTAL
Intervention: Inpatient or residential treatment
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous only
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 515
Study: 31907323

Group type: EXPERIMENTAL
Intervention: Pay for Performance (P4P) group paid $150 plus $10 bonus for each of five outcome measures (max $300)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pay for Performance (P4P) group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group received $200
Number of subjects: 35
Study: 30903685

Group type: EXPERIMENTAL
Intervention: ASTRAL-MP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASTRAL-MP (GPU version)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASTRAL (single-threaded implementation)
Number of subjects: 0
Study: 28318625

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 60
Study: 25380193

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg inhaled via Respimat® Soft Mist™ Inhaler
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg inhaled via Respimat® Soft Mist™ Inhaler
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Tiotropium (2.5 μg or 5 μg)
Number of subjects: 92
Study: 22930695

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 19700209

Group type: EXPERIMENTAL
Intervention: Distal protection during PCI
Number of subjects: 626

Group type: COMPARATOR
Intervention: Conventional PCI (without distal protection)
Number of subjects: 626
Study: 19457474

Group type: EXPERIMENTAL
Intervention: Dissonance intervention (four-week duration)
Number of subjects: 71
Study: 16762763

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment for acute PE
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Patients with pulmonary hypertension
Number of subjects: 220
Study: 15541822

Group type: EXPERIMENTAL
Intervention: BMS-275291
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 11316710

Group type: EXPERIMENTAL
Intervention: High dose vitamin A and E supplementation (25,000 IU retinol palmitate and 230 mg alpha tocopheryl nicotinate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9409295

Group type: EXPERIMENTAL
Intervention: Cyclic oral estradiol combined with progesterone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol combined with progesterone
Number of subjects: 45

Group type: COMPARATOR
Intervention: No hormonal treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 8287641

Group type: EXPERIMENTAL
Intervention: E + HC (hyperinsulinaemic clamp followed by hypoglycaemia)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HC (hypoglycaemic clamp)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: II (insulin infusion only)
Number of subjects: 10
Study: 2882967

Group type: EXPERIMENTAL
Intervention: Experimental treatment (101 adults and 45 adolescents)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard treatment (90 adults and 42 adolescents)
Number of subjects: 278
Study: 31287236

Group type: EXPERIMENTAL
Intervention: Coadministration of gemfibrozil 600 mg BID with brigatinib 90 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coadministration of itraconazole 200 mg BID with brigatinib 90 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coadministration of rifampin 600 mg QD with brigatinib 180 mg
Number of subjects: 60
Study: 30008434

Group type: EXPERIMENTAL
Intervention: Hit n Run video game
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy Eating Step by Step (HESbS) brochure
Number of subjects: 104
Study: 27307144

Group type: EXPERIMENTAL
Intervention: Targeted outpatient rescreening through collaboration with the WIC program
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non-WIC infants in the same hospitals (nonintervention)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non-WIC infants at nonintervention hospitals
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: WIC intervention group
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non-WIC infants
Number of subjects: 260
Study: 24789256

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment
Number of subjects: 9
Study: 22452373

Group type: EXPERIMENTAL
Intervention: Persistent atrial fibrillation group
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (no persistent atrial fibrillation)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 308
Study: 20402707

Group type: EXPERIMENTAL
Intervention: Flax oil capsules containing 550 mg alpha‐LNA per 1 gram, titrated to 12 capsules per day over 16 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Flax oil (alpha‐LNA)
Number of subjects: 51
Study: 18562250

Group type: EXPERIMENTAL
Intervention: 1 mug/kg fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30